Lilly 3Q Revenues: $6.8 billion (+18%) 3Q Earnings: $1.1 billion (-8%) YTD Revenues: $20.3 billion (+19%) YTD Earnings: $3.9 billion (-5%) Comments:  Key growth products, consisting of Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Tyvyt, Retevmo and Cyramza, contributed 17 percentage points of revenue growth and represented approximately 58 percent of total revenue in the third quarter, excluding revenue from COVID-19 therapies. COVID-19 antibodies sales were $217.1 million in ...